Efficacy and Safety of Nefecon in Patients w/ Primary IgA (Immunoglobulin A) Nephropathy (Nefigard)
Diseases of the Kidney & Urinary Tract
What is the purpose of this trial?
The overall aim of the study is to evaluate the efficacy, safety, and tolerability of Nefecon 16 mg per day in the treatment of patients with primary IgAN (Immunoglobulin A nephropathy) at risk of progressing to end-stage renal disease (ESRD), despite maximum tolerated treatment with renin-angiotensin system (RAS) blockade using angiotensin converting enzyme inhibitors (ACEIs) or angiotensin II type I receptor blockers (ARBs).
- Ages18 years and older
- Trial withCalliditas AB
- Start Date04/15/2019
- End Date10/30/2020
- Last Updated10/30/2019
- Study HIC#2000024668